Growth Opportunities in Global Vaccines Market, Forecast to 2024

Growth Opportunities in Global Vaccines Market, Forecast to 2024

Increased Investment in Adult Immunization and Improved Mammalian Cell-culture Expression Systems will Drive Growth and Profitability

RELEASE DATE
25-Apr-2019
REGION
North America
Research Code: ME98-01-00-00-00
SKU: HC03167-NA-MT_23086
$4,950.00
In stock
SKU
HC03167-NA-MT_23086
$4,950.00
Links

Pay by invoice

ENQUIRE NOW

Description

The report provides an overview of the global vaccine market estimating the market size broken down by different segments. Vaccines, though a sub-set of biologics, have a completely different dynamic. Not only are they largely designed for a healthy cohort but are also exponentially influenced by government actions and policies. While old generation vaccines continue to experience growth, the increasing prevalence of cancer and infectious diseases is fueling the growth of the vaccine market.

The vaccines market is categorized on the basis of the production system, antigens, procurement system, and end users. The study also dives deeper into different technological, geographical, and therapeutic opportunities with an objective assessment of the disclosed pipeline. While the vaccines market has been characterized by highly commoditized and mature product groups, it is reinventing itself and following the pharma path of innovation.


Research Highlights

The study covers innovation across the vaccine development spectrum, including manufacturing processes (e.g., cell-based and recombinant vaccines), new delivery systems (e.g., needle-free), as well as novel candidates and improvements to existing vaccines (e.g., use of improved platforms or adjuvants). The study also covers mRNA technology and its significant potential for rapid and versatile manufacturing, reduced industrialization costs for multiple vaccines, and the improved breadth of immune response for infectious disease vaccines. Additionally, the study captures the competitive landscape and the different strategies employed by companies to stay ahead of the curve. It also identifies the game-changing companies that are leading innovation from the front. Acknowledging that the market continues to remain oligopolistic, with 4 companies leading the pack, the study identifies opportunities for mid and small segment companies to tap this market. Vaccines have a high entry barrier for generic players and there is a potential to generate blockbuster sales (as established by Pfizer’s Prevnar and GSK’s Gardasil), which make the market lucrative for new players.

The study lays down strategic imperatives for companies to recalibrate their business models and be future ready. In conjunction with the core manufacturers, the research service also provides in-depth analysis of other ecosystem stakeholders such as logistic service providers, contract manufacturers, investors, and advocacy groups. Information is also given on some of the leading M&A activities impacting the market as well as unconventional collaboration agreements laying the foundation for propelling innovations toward licensure and delivery. Furthermore, present and future market trends like increasing price transparency and vaccines affordability, which would shape the market, have been discussed.

Key Issues Addressed

  • What are the biggest opportunities for small and mid-sized companies in the global vaccines market?
  • How are the various regions around the globe positioned to monetize the market opportunities? What are the key regional barriers to entry?
  • What is the total market size and projected growth of the global vaccines market? Which are the largest growth segments to be pursued?

Author: Khushbu Jain

Table of Contents

Purpose of this Study

5-step Process to Transformational Growth

Key Findings

Key Questions this Study will Answer

Market Engineering Measurements

Big Market Themes

Strategic Imperatives for Vaccine Ecosystem Stakeholders

Scope

Vaccine Type by Production Systems

Market Drivers and Restraints

Dichotomy of Public and Private Markets

Current State of Coverage

Tapering Blockbuster Products

Examples of Strategies at Work

Unmet Need in Vaccine-preventable Diseases

Anticipated Key Product Launches

Pipeline Analysis

Global Initiatives for Advancement in Vaccines

Methodology

Market Engineering Measurements

Forecast Assumptions

Key Market Assumptions

Revenue Forecast

Percent Revenue Breakdown by End User

Percent Revenue Breakdown by Geography

Percent Revenue Breakdown by Production System

Percent Revenue Forecast by Antigen Type

Market Share Analysis

Competitive Environment

Competitive Landscape and Benchmarking

Vendor Landscape

Key Companies to Watch

Key Companies to Watch (continued)

Collaboration Assessment

Collaboration Assessment (continued)

Macro to Micro Visioning

Top Areas of Innovations in Vaccines

Uberization of Vaccines

5 Major Growth Opportunities

Growth Opportunity 1—Respiratory Syncytial Virus

Business Opportunity by Therapeutic Area

RSV Pipeline Analysis

Growth Opportunity 2—DNA Vaccines

DNA Vaccine Pipeline Analysis

Growth Opportunity 3—Emerging Markets

Need for Customized Solutions

APAC Vaccine Pipeline Analysis

Growth Opportunity 4—Needle-free Vaccine Delivery

Growth Opportunity 5—Cold-chain Solutions

Magnitude of the Supply-chain Challenge

Growth Opportunity Matrix

Products Going Off-patent Between 2019 and 2024

Top 3 Predictions for the Market

Legal Disclaimer

Examples of Tiered Pricing

Abbreviations

Public Markets Overview

List of Exhibits

List of Exhibits (continued)

Related Research

Global Cell Therapy Market—Companies to Action, 2018

Release Date: 11-Mar-19
Region: North America

Mergers and Acquisitions in the Global Life Sciences Industry, 2018

Release Date: 07-Mar-19
Region: North America
The report provides an overview of the global vaccine market estimating the market size broken down by different segments. Vaccines, though a sub-set of biologics, have a completely different dynamic. Not only are they largely designed for a healthy cohort but are also exponentially influenced by government actions and policies. While old generation vaccines continue to experience growth, the increasing prevalence of cancer and infectious diseases is fueling the growth of the vaccine market. The vaccines market is categorized on the basis of the production system, antigens, procurement system, and end users. The study also dives deeper into different technological, geographical, and therapeutic opportunities with an objective assessment of the disclosed pipeline. While the vaccines market has been characterized by highly commoditized and mature product groups, it is reinventing itself and following the pharma path of innovation.--BEGIN PROMO--

Research Highlights

The study covers innovation across the vaccine development spectrum, including manufacturing processes (e.g., cell-based and recombinant vaccines), new delivery systems (e.g., needle-free), as well as novel candidates and improvements to existing vaccines (e.g., use of improved platforms or adjuvants). The study also covers mRNA technology and its significant potential for rapid and versatile manufacturing, reduced industrialization costs for multiple vaccines, and the improved breadth of immune response for infectious disease vaccines. Additionally, the study captures the competitive landscape and the different strategies employed by companies to stay ahead of the curve. It also identifies the game-changing companies that are leading innovation from the front. Acknowledging that the market continues to remain oligopolistic, with 4 companies leading the pack, the study identifies opportunities for mid and small segment companies to tap this market. Vaccines have a high entry bar

More Information
No Index No
Podcast No
Author Khushbu Jain
Industries Healthcare
WIP Number ME98-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,9571-B1,99C1-B1,9568-B1,9611-B1